DEFA14A: Recursion Pharmaceuticals Highlights Potential Synergies in Exscientia Acquisition

Recursion Pharmaceuticals emphasizes the strategic rationale behind its proposed acquisition of Exscientia, focusing on the convergence of biology and chemistry expertise to enhance drug discovery.

Summary

• Recursion Pharmaceuticals is pursuing the acquisition of Exscientia to create an AI-first, full-stack small-molecule drug discovery engine.
• The merger aims to combine Recursion's strength in decoding biology with Exscientia's expertise in chemistry.
• Najat Khan, Recursion's Chief R&D Officer and Chief Commercial Officer, highlights the potential for first-in-class and best-in-class programs through this combination.
• The combined company will have partnerships with Sanofi, Roche/Genentech, Merck & Co., and Bayer, with about ten programs in the external pipeline across oncology, immunology, and neuroscience.
• The acquisition is expected to expand Recursion's chemistry capabilities and address challenges in lead optimization and toxicity prediction.
• The companies filed a preliminary joint proxy statement with the SEC on September 17, 2024, related to the proposed transaction.
• The transaction is expected to close by early 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the proposed acquisition, highlighting potential synergies and benefits for both companies. The tone is optimistic and forward-looking.

Positives

• The acquisition creates a comprehensive AI-first drug discovery engine.
• The merger combines strengths in biology and chemistry, potentially leading to better drug candidates.
• The combined company has a diverse pipeline and partnerships with leading pharmaceutical companies.
• The acquisition is expected to improve lead optimization and toxicity prediction.
• The company anticipates potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion in revenue before royalties over the course of the partnerships.

Risks

• The acquisition may not be completed if Recursion's stockholders or Exscientia's shareholders do not approve the transaction.
• The companies may not be able to successfully integrate Exscientia's business with Recursion's business.
• The combined company may not be able to realize the expected benefits of the acquisition, including cost synergies.
• Legal proceedings may be instituted against Recursion or Exscientia in connection with the proposed combination.
• Economic, market, or business conditions may negatively affect the combined company's operations, revenue, and cash flow.

Future Outlook

The combined company aims to deliver better treatments to patients faster and at a lower cost, discover and translate higher quality medicines more efficiently and at a higher scale, and enable a full-stack technology-enabled platform.

Management Comments

• Najat Khan believes the acquisition will expand Recursion's chemistry capabilities and address real challenges in drug discovery.
• Najat Khan states that the potential combination gives the convergence of excellence in biology and excellence in chemistry, to get to both first-in-class and best-in-class programmes.

Industry Context

The acquisition reflects a growing trend in the pharmaceutical industry towards leveraging AI and machine learning to accelerate drug discovery and development.

Comparison to Industry Standards

• The merger of Recursion and Exscientia aims to create a fully integrated AI-driven drug discovery platform, similar to efforts by companies like Atomwise and Insitro.
• The combined company's partnerships with major pharmaceutical firms like Sanofi, Roche/Genentech, Merck & Co., and Bayer are comparable to other techbio companies that collaborate with established players to validate their technologies and pipelines.
• The focus on both first-in-class and best-in-class molecules aligns with industry trends towards developing innovative and improved therapies.

Management Changes

Stakeholder Impact

• Shareholders of both Recursion and Exscientia are impacted by the proposed acquisition and will vote on the transaction.
• Employees of both companies may experience changes in their roles and responsibilities as a result of the integration.
• Customers and partners of both companies may benefit from the combined company's enhanced capabilities and expanded pipeline.

Next Steps

• Obtain Recursion stockholder approval.
• Obtain Exscientia shareholder approval.
• Obtain the sanction of the High Court of Justice of England and Wales to the Scheme of Arrangement.
• Receive required regulatory approvals.
• Close the transaction by early 2025.

Key Dates

Keywords

Recursion, Exscientia, acquisition, AI, drug discovery, merger, pharmaceuticals, biology, chemistry